osimertinib (Tagrisso) -

osimertinib (Tagrisso)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Respiratory disorders
Summary
The SMC has accepted for restricted use within NHS Scotland, osimertinib (Tagrisso) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).
UKMi comment
It is restricted to use in patients who have received previous treatment with an EGFR tyrosine kinase inhibitor. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of osimertinib.

The National Institute for Health and Care Excellence has previously advised that osimertinib is recommended as an option for use within the Cancer Drugs Fund for this indication (Oct 2016).
Related links: Link to NICE TA 416